Real-World data on osimertinib for EGFR lung cancer in australia
NCT ID NCT07213076
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 23 times
Summary
This study reviewed medical records of 350 Australian adults with advanced EGFR-mutant non-small cell lung cancer to see how they responded to the drug osimertinib, either as their first or second treatment. Researchers tracked how long patients stayed on the drug and their overall survival. The goal was to understand real-world treatment patterns and outcomes, not to test a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Melbourne, Victoria, 3000, Australia
Conditions
Explore the condition pages connected to this study.